EP0572470A1 - Procede de production d'une composition medicamenteuse permettant d'obtenir un effet de protection de la moelle osseuse et un effet anti-neoplastique - Google Patents

Procede de production d'une composition medicamenteuse permettant d'obtenir un effet de protection de la moelle osseuse et un effet anti-neoplastique

Info

Publication number
EP0572470A1
EP0572470A1 EP92904934A EP92904934A EP0572470A1 EP 0572470 A1 EP0572470 A1 EP 0572470A1 EP 92904934 A EP92904934 A EP 92904934A EP 92904934 A EP92904934 A EP 92904934A EP 0572470 A1 EP0572470 A1 EP 0572470A1
Authority
EP
European Patent Office
Prior art keywords
extract
coli
metabolic products
ginkgo
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92904934A
Other languages
German (de)
English (en)
Inventor
Helmut Scholle
Clemens Unger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0572470A1 publication Critical patent/EP0572470A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to the manufacture of a medicament preparation for achieving a bone marrow-protective effect by stimulating leukocyte proliferation, a pharmaceutical preparation which contains such a medicament, and a medicament kit and a method for stimulating leukocyte proliferation and for producing an antineoplastic Effect.
  • leukopenia occurs in patients who are treated with chemotherapy with cytostatics or with radiation, which can lead to a possibly severe anemia through thrombopenia. For this reason, cytostatics cannot be administered in unrestrictedly high doses in chemotherapy.
  • the aim of the invention is therefore to overcome the aforementioned parts.
  • Such a product is already marketed under the name Coiibi ⁇ genS as a medicament by Laves-Arzneistoff GmbH GmbH Ronnenberg / Hanover in Germany, both as an oral solution and as an injectable solution.
  • an ampoule intended for injection contains 2 ml of a protein-free solution of the metabolic products of four trillion E. coli bacteria.
  • Indications for this medicinal product are intestinal disorders of organic and functional genesis, especially with spastic symptoms, Crohn's disease, ulcerative collitis, urticaria, eczema, purpura, food allergy, bronchial asthma, spastic bronchitis, acne and migraines.
  • Indications for the oral drinking solution are disorders of the motility and permeability of the intestinal mucosa, their damage, damage to the intestinal flora after the use of chemotherapy and antibiotic therapy, intestinal metabolic and resorption disorders, gastroenteritis salmonellosa, colidyspepsia, especially in small children and infants, endogenous enzyme, chronic loss of appetite and umbilical colic indicated.
  • a filtrate essentially shows a polysaccharide component which consists mainly of glucose, galactose and xylose. Also included
  • REPLACEMENT LEAF are peptide components which essentially contain asparagine, glutamic acid, alanine, glycerol, lysine and leucine. There is also a small proportion of fatty acids, in particular palmitic, stearic and oleic acid. Finally, small amounts of 3-hydroxymyristic acid and small amounts of bacterial endotoxin can also be found in this filtered solution from E. coli extract.
  • the invention therefore relates to a method for producing a medicament for the above-mentioned new indications using a bacteria- and protein-free filtrate containing the metabolic products of E. coli cultures.
  • a method for producing a medicament for the above-mentioned new indications using a bacteria- and protein-free filtrate containing the metabolic products of E. coli cultures is very particularly suitable for use in chemotherapy with cytostatics on cancer patients.
  • the agent is also effective in radiation therapy.
  • the patient is usually given at least one of the two pharmaceutical preparations in advance over a period of 2 hours to 5 minutes, expediently over 1 to 0.5 hours before administration of the cytostatic agent or radiation. All of the two drugs are preferably administered. Even if the pre-release is carried out 1 to 2 days before the radiation and / or chemotherapy, there are good effects. Even with a continuous oral. Administration, the surprising effect on which the invention is based is found.
  • the protective effect on which the invention is based can be achieved for all known chemical cytostatics.
  • the combination with the medicament produced according to the invention is subject to the usual conditions known to the doctor. selected for the respective tumor type.
  • Preferred cytostatics for application to colon and gastric carcinoma are fluorouracil, and for breast cancer fluorouracil, cyclophosphate, epirubicin, methotrexate, to squamous cell carcinoma. Vepesid and Platinex.
  • the medicament produced according to the invention has a particularly good effect on squamous cell carcinoma.
  • the pharmaceutical manufactured according to the invention is therefore particularly suitable for the treatment of those tumors which have already undergone multiple cytotoxic chemotherapy and which otherwise show a very unfavorable response.
  • the medicament produced in accordance with the invention is therefore particularly particularly suitable for the treatment of metastatic tumors.
  • the invention therefore also relates to a pharmaceutical preparation which, in combination, precedes the metabolic products.
  • E. coli-containing extract as a bacterial and protein-rich filtrate and an extract from Ginkgo biloba leaves.
  • the production of such extracts is known and these can already be purchased from various manufacturers. For example, Dr. Willmar Schwabe, Düsseldorf, Germany marketed an extract standardized on ginkgo-flavone glycosides under the name TeboninR as a drug, drops and infusion ampoules.
  • antineoplastic effect of the combined drugs cytostatics and the E. coli metabolic products can be increased even further if additional substances are administered which are contained in an extract from Ginkgo biloba leaves. Through the additional administration of such an extract, even those tumors and metastases show remission that have not previously responded to any medication or any other form of therapy. An increased effect can also be found in radiation therapy.
  • the invention therefore also relates to a pharmaceutical preparation which, in combination, contains the metabolites from E. coli as a bacteria- and protein-free filtrate and an extract from Ginkgo biloba leaves.
  • the pharmaceutical preparation can contain the metabolic products from E. coli and the extract from ginkgo biloba leaves both in mixed form and spatially separated for simultaneous, separate or staggered use.
  • the extract from ginkgo leaves according to ginkgo-flavone glycosides is preferably contained in the pharmaceutical preparation according to the invention in a standardized manner.
  • coli metabolic products and / or the extract from ginkgo leaves is preferably in an intravenously administrable form and expediently as an infusion and / or as injection ampoules.
  • the effect according to the invention can also be achieved by continuous oral administration of ginkgo extract and E. coli filtrate.
  • the pharmaceutical preparation according to the invention additionally contains a cytostatic in spatially separate form for simultaneous, separate or staggered use.
  • the pharmaceutical preparation according to the invention is preferably used before the use of radiation and / or cytostatics applied as a default. It is preferably suitable for the treatment of tumor diseases, in particular for the treatment of breast cancer, prostate cancer, gastric cancer, esophageal cancer, squamous cell carcinoma, sarcoma, bile duct cancer, colon cancer or melanoma.
  • Example 1 As described in Example 1, other patients who had gastric carcinoma, esophageal carcinoma and squamous cell carcinoma. and who previously did not respond to therapy, successfully with a combination of ginkgo extract, E. coli filtrate and cytostatic treated. In all cases a clear remission could be achieved by administration of the pharmaceutical combination according to the invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un médicament ayant un effet anti-néoplastique et un effet protecteur de la moëlle osseuse par stimulation de la prolifération des leucocytes permet d'éliminer les effets préjudiciables de l'irradiation ou de l'administration de médicaments cytostatiques chez des patients souffrant de cancer. Un médicament de ce type contient au moins un ou plusieurs produits métaboliques extraits de cultures d'E. coli sous forme de filtrat exempt de bactéries et de protéines. Dans un mode préféré de réalisation, un médicament de ce type contient en outre un extrait de feuilles de ginkgo-biloba. Ce médicament contient sous forme de kit les substances actives combinées afin d'être administrées en même temps, séparément ou successivement, éventuellement avec un agent cytostatique.
EP92904934A 1991-02-22 1992-02-20 Procede de production d'une composition medicamenteuse permettant d'obtenir un effet de protection de la moelle osseuse et un effet anti-neoplastique Withdrawn EP0572470A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4105570A DE4105570A1 (de) 1991-02-22 1991-02-22 Verwendung eines bakterien- und eiweissfreien filtrats
DE4105570 1991-02-22

Publications (1)

Publication Number Publication Date
EP0572470A1 true EP0572470A1 (fr) 1993-12-08

Family

ID=6425657

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92904934A Withdrawn EP0572470A1 (fr) 1991-02-22 1992-02-20 Procede de production d'une composition medicamenteuse permettant d'obtenir un effet de protection de la moelle osseuse et un effet anti-neoplastique

Country Status (7)

Country Link
EP (1) EP0572470A1 (fr)
JP (1) JPH06505016A (fr)
AU (1) AU1246692A (fr)
CA (1) CA2101645A1 (fr)
DE (2) DE4105570A1 (fr)
HU (1) HUT74576A (fr)
WO (1) WO1992014478A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4308443C2 (de) * 1993-03-17 1996-09-19 Laves Hans Georg Arzneimittel zur Behandlung von Retrovirusinfektionen
CA2378052C (fr) * 1999-08-12 2010-03-23 Katy Drieu Utilisation d'extrait de ginkgo

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2639830B1 (fr) * 1988-12-02 1991-03-22 Beljanski Mirko Composition antivirale et ses applications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9214478A1 *

Also Published As

Publication number Publication date
DE4290471D2 (de) 1994-04-28
DE4105570A1 (de) 1992-08-27
JPH06505016A (ja) 1994-06-09
CA2101645A1 (fr) 1992-08-23
WO1992014478A1 (fr) 1992-09-03
AU1246692A (en) 1992-09-15
HU9302387D0 (en) 1993-11-29
HUT74576A (en) 1997-01-28

Similar Documents

Publication Publication Date Title
EP0142641B1 (fr) Moyen et produit pour le diagnostic et la thérapie de tumeurs ainsi que pour le traitement de déficiences du système immunitaire cellulaire et humoral
DE3541945A1 (de) Immunstimulierend wirkende polysaccharide aus zellkulturen von echinacea purpurea (l.) moench und echinacea angustifolia, d.c. verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen
EP0263417A1 (fr) Utilisation d'hyaluronidase
DE3115080A1 (de) Arzneimittel fuer die orale verabreichung und verfahren zu seiner herstellung
DE3782430T2 (de) Verwendung eines trypsininhibitors des kunitztyps aus sojabohnen und seiner derivate zur herstellung von medikamenten und denselben enthaltendes agens.
DE60204067T2 (de) Verwendung von Xanthenon-4-Essigsäure zur Herstellung eines Medikaments für die Behandlung von hyperproliferativer Störungen
DE60030567T2 (de) Aus muskeln abstammenden wirkstoffe enthaltende zusammensetzung
EP0572470A1 (fr) Procede de production d'une composition medicamenteuse permettant d'obtenir un effet de protection de la moelle osseuse et un effet anti-neoplastique
EP0359951B1 (fr) Utilisation d'un extrait de ginkgo contre les métastases
DE3721562A1 (de) Verwendung exogener ganglioside als schutzfaktor bei tumorerkrankungen
DE2715384C3 (de) Arzneimittel gegen Diarrhöen
DE4008033A1 (de) Verwendung von lactoferrin zur bekaempfung der toxischen wirkung des endotoxins
DE10326821A1 (de) Pharmazeutische Kombinationspräparate zur Krebstherapie
DE19738484A1 (de) Verwendung von N-Propanoyl-Mannosamin als Medikament
JPS5821655A (ja) 治療効果を有する新規化合物およびその製造方法
DE3334751C2 (fr)
EP0210295B1 (fr) Médicament pour le traitement d'entérocolite chronique inflammatoire
Leupold et al. Nichtketotische Hyperglycinämie
DE68917830T2 (de) Verfahren zur Herstellung einer physiologisch aktiven Substanz mit Antikrebs-Aktivität und so erhaltene Substanz.
DE3410848A1 (de) Arzneimittel zur behandlung von tumoren in der metastasenphase
DE2265235A1 (de) Heilmittel
DE3825186A1 (de) Oral verabreichbare, lektine enthaltende zubereitungen zur behandlung von metastasen
Kluge et al. Über den Ursprung und das Verhalten der OCT im Liquor cerebrospinalis bei neurologisch-psychiatrischen Erkrankungen
DE890261C (de) Verfahren zur Herstellung von Reizstoffen
Fekl et al. Stoffwechseladaptierte Ernährung im Konzept der klinischen Ernährungstherapie–Erfolge und Ausblick

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19930715

17Q First examination report despatched

Effective date: 19950103

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950608